Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference95 articles.
1. Cancer statistics, 2008.;Jemal;CA Cancer J Clin,2008
2. Estimates of the cancer incidence and mortality in Europe in 2006.;Ferlay;Ann Oncol,2007
3. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.;Slamon;Science,1989
4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.;Slamon;Science,1987
5. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.;Sjogren;J Clin Oncol,1998
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines;Journal of Nanobiotechnology;2024-06-20
2. Combined SERS-Raman screening of HER2-overexpressing or silenced breast cancer cell lines;2024-01-15
3. Targeted PLGA–Chitosan Nanoparticles for NIR-Triggered Phototherapy and Imaging of HER2-Positive Tumors;Pharmaceutics;2023-12-20
4. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab;Pathology - Research and Practice;2023-12
5. Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations;International Immunopharmacology;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3